Abstract | PURPOSE: As chemotherapy has not been extensively studied in patients with lymphoma of the mucosa-associated lymphoid tissue (MALT), we initiated a prospective study to evaluate the activity of the nucleoside analog cladribine (2-chlorodeoxyadenosine [2-CdA]) in this disease. PATIENTS AND METHODS: Patients with histologically verified MALT-type lymphoma were enrolled. 2-CdA was administered at a dose of 0.12 mg/kg body weight on 5 consecutive days, as a 2-hour infusion. Cycles were repeated every 4 weeks for a maximum of six cycles. RESULTS: Nineteen patients with gastric and seven patients with extragastric MALT lymphoma were enrolled. All patients were chemotherapy-naive, and two had been locally irradiated before systemic relapse of the lymphoma. A total of 102 cycles was administered to our patients (median number of cycles per patient, four). All 25 assessable patients responded to treatment: 21 patients (84%) achieved complete remission (CR) and four patients achieved partial remission. All patients (100%) with gastric presentation, but only three patients (43%) with extragastric presentation, achieved CR. Toxicities were moderate and mainly hematologic and required dose reduction and/or premature discontinuation of therapy in only three cases. Two patients died from vascular events, one shortly after the first cycle because of myocardial infarction and the other from stroke 3 months after the second course. Three patients relapsed after 13, 18, and 22 months and one patient showed progressive disease after 15 months. At present, 24 patients are alive at a median follow-up time of 32 months. CONCLUSION: Our data demonstrate that 2-CdA is highly effective in inducing CR in 84% of patients with MALT-type lymphoma.
|
Authors | Gerald Jäger, Peter Neumeister, Ruth Brezinschek, Thomas Hinterleitner, Wolfgang Fiebiger, Melitta Penz, Hans J Neumann, Brigitte Mlineritsch, Maria DeSantis, Franz Quehenberger, Andreas Chott, Christine Beham-Schmid, Gerald Höfler, Werner Linkesch, Markus Raderer |
Journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology
(J Clin Oncol)
Vol. 20
Issue 18
Pg. 3872-7
(Sep 15 2002)
ISSN: 0732-183X [Print] United States |
PMID | 12228207
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Cladribine
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(adverse effects, therapeutic use)
- B-Lymphocytes
- Cladribine
(adverse effects, therapeutic use)
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lacrimal Apparatus
(pathology)
- Liver
(pathology)
- Lymphoid Tissue
(drug effects, pathology)
- Lymphoma, B-Cell, Marginal Zone
(drug therapy, pathology)
- Male
- Middle Aged
- Neoplasm Staging
- Parotid Gland
(pathology)
- Prospective Studies
- Remission Induction
- Stomach Neoplasms
(drug therapy, pathology)
- Survival Rate
|